Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19
RCT showing improved viral clearance with bebtelovimab. Results refer to the placebo controlled portion of the trial.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 Planas.
risk of hospitalization, 27.0% higher, RR 1.27, p = 1.00, treatment 5 of 252 (2.0%), control 2 of 128 (1.6%), combined bebtelovimab arms.
|
risk of hospitalization, 2.4% higher, RR 1.02, p = 1.00, treatment 2 of 125 (1.6%), control 2 of 128 (1.6%), bebtelovimab only.
|
recovery time, 25.0% lower, relative time 0.75, treatment 127, control 128.
|
relative viral load reduction, 4.0% better, RR 0.96, p < 0.001, treatment mean 3.77 (±0.21) n=125, control mean 3.62 (±0.2) n=128, day 7.
|
relative viral load reduction, 29.7% better, RR 0.70, p < 0.001, treatment mean 3.03 (±0.19) n=125, control mean 2.13 (±0.19) n=128, day 5.
|
relative viral load reduction, 15.4% better, RR 0.85, p < 0.001, treatment mean 1.43 (±0.2) n=125, control mean 1.21 (±0.2) n=128, day 3.
|
risk of no viral clearance, 38.6% lower, RR 0.61, p = 0.12, treatment 15 of 125 (12.0%), control 25 of 128 (19.5%), NNT 13, persistently high viral load, day 7, primary outcome.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Dougan et al., 12 Mar 2022, Randomized Controlled Trial, USA, preprint, 22 authors, study period 19 April, 2021 - 19 July, 2021, trial
NCT04634409 (history) (BLAZE-4).
Contact:
robert.gottlieb@bswhealth.org.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.03.10.22272100; this version posted March 12, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly
neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19.
Authors: Michael Dougan, MD, PhD1; Masoud Azizad, MD2, Peter Chen, MD3; Barry Feldman,
MD4; Matthew Frieman, PhD5; Awawu Igbinadolor, MD6; Princy Kumar, MD7; Jason Morris,
MD8; Jeffrey Potts, MD9; Lauren Baracco, BS5; Lisa Macpherson, MSPHc10; Nicole L.
Kallewaard, PhD10; Dipak R. Patel, MD, PhD10; Matthew M. Hufford, PhD10; Linda Wietecha,
MSc10; Emmanuel Chigutsa, PhD10; Sarah L. Demmon, MS10; Bryan E. Jones, PhD10; Ajay Nirula,
MD, PhD10; Daniel M. Skovronsky, MD, PhD10; Mark Williams, MD, FCCM, FCCP10; Robert L.
Gottlieb, MD, PhD11.
Affiliations: 1Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA;
2Valley Clinical Trials, Northridge, CA, USA; 3Cedars–Sinai Medical Center, Los Angeles, CA,
USA; 4Millennium Medical Group, Farmington Hills, MI, USA; 5University of Maryland School
of Medicine, Baltimore, MD; 6Monroe Biomedical Research, Monroe, NC, USA; 7Georgetown
University, Washington, DC, USA; 8Clinical Trials of Southwest Louisiana, Lake Charles, LA,
USA; 9Great Lakes Research Group, Inc., Bay City, MI, USA; 10Eli Lilly and Company,
Indianapolis, IN, USA. 11Baylor University Medical Center and Baylor Scott & White Research
Institute, Dallas, TX, USA;
Corresponding author: Robert L. Gottlieb, MD, PhD, Baylor University Medical Center and
Baylor Scott & White Research Institute, Dallas, TX, USA. E-mail:
Robert.Gottlieb@BSWHealth.org. Phone: +1-214-820-6856 (Office).
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
1
medRxiv preprint doi: https://doi.org/10.1101/2022.03.10.22272100; this version posted March 12, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
BACKGROUND: Bebtelovimab is a potent, fully human IgG1 monoclonal antibody (mAb)
targeting the S-protein of SARS-CoV-2, with broad neutralizing activity to all currently known
SARS-CoV-2 variants of concern, including omicron variant lineages. Specialized
developmental approaches accelerated the initiation of a clinical trial designed to evaluate
the efficacy and safety of bebtelovimab alone (BEB) or together with bamlanivimab (BAM)
and etesevimab (ETE) delivered via slow intravenous push for the treatment of mild-tomoderate COVID-19.
METHODS: This portion of the phase 2, BLAZE-4 trial (J2X-MC-PYAH; NCT04634409) enrolled
714 patients (between May and July 2021) with mild-to-moderate COVID-19 within 3 days (≤3
days) of laboratory diagnosis of SARS-CoV-2 infection. Patients at low risk for severe COVID19 were randomized 1:1:1 (double-blinded) to placebo, BEB 175 mg, or BEB 175 mg+BAM 700
mg+ETE 1400 mg (BEB+BAM+ETE). Patients at high risk for progression to severe COVID-19
were randomized 2:1 (open-label) to BEB or BEB+BAM+ETE, and a subsequent treatment arm
enrolled..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit